Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluation
Authors:
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 83, 81-87
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Statistical Monitoring of Safety in Clinical TrialsStatistics in Biopharmaceutical Research, 2016
- Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an Investigational New Drug ApplicationTherapeutic Innovation & Regulatory Science, 2014
- Safety Monitoring in Clinical TrialsPharmaceutics, 2013
- Continuous safety monitoring for randomized controlled clinical trials with blinded treatment informationContemporary Clinical Trials, 2011
- Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical TrialsJournal of Biopharmaceutical Statistics, 2011
- Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting teamClinical Trials, 2009
- Sentinel Event Methods for Monitoring Unanticipated Adverse Events2007
- Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare eventsStatistics in Medicine, 2006
- Strong Control, Conservative Point Estimation and Simultaneous Conservative Consistency of False Discovery Rates: A Unified ApproachJournal of the Royal Statistical Society Series B: Statistical Methodology, 2003
- The positive false discovery rate: a Bayesian interpretation and the q-valueThe Annals of Statistics, 2003